BackAmneal Pharmaceuticals Overview
Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

Amneal Pharmaceuticals Target Price

See Amneal Pharmaceuticals's analyst price targets ($23) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$19.95

Average Target Price

$23.2916.7% upside

7 analysts in the last 4 months

High: $27 | Low: $20

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-10-29Goldman Sachs$2420.3% upsideOpen
2026-09-23Oppenheimer$2735.3% upsideOpen
2026-09-17Barclays$200.3% upsideOpen
2026-09-09Leerink Partners$2315.3% upsideOpen
2026-08-03UBS$2525.3% upsideOpen
2026-07-31Goldman Sachs$215.3% upsideOpen
2026-07-15UBSAshwani Verma$2315.3% upsideOpen
2026-05-20BarclaysGlen Santangelo$1619.8% downsideOpen
2026-04-17UBSAshwani Verma$194.8% downsideOpen
2026-03-02Truist FinancialLes Sulewski$1714.8% downsideOpen
2026-01-07Truist Financial$1524.8% downsideOpen
2025-12-08Barclays$1524.8% downsideOpen
2025-03-03Barclays$1144.9% downsideOpen
2024-11-11Piper SandlerDavid Amsellem$1144.9% downsideOpen
2024-10-02Truist FinancialLes Sulewski$1239.8% downsideOpen
2024-10-01Truist FinancialLes Sulewski$1049.9% downsideOpen
2024-05-03Truist FinancialLes Sulewski$954.9% downsideOpen
2024-03-21Piper SandlerDavid Amsellem$859.9% downsideOpen
2022-08-08Goldman Sachs$479.9% downsideOpen

Amneal Pharmaceuticals (AMRX) FAQ

Amneal Pharmaceuticals's target price stands at $23. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $23 for AMRX implies 16.7% upside versus today's price ($19.95). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Amneal Pharmaceuticals's target price evolved across reporting periods, while the comparison chart places AMRX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Amneal Pharmaceuticals's reading of $23 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.